| dc.contributor.author | Kapran, Y. | |
| dc.contributor.author | Bayraktaroglu, T. | |
| dc.contributor.author | Tanakol, R. | |
| dc.contributor.author | Alagoel, F. | |
| dc.contributor.author | Boztepe, H. | |
| dc.date.accessioned | 2021-03-04T18:00:13Z | |
| dc.date.available | 2021-03-04T18:00:13Z | |
| dc.date.issued | 2010 | |
| dc.identifier.citation | Bayraktaroglu T., Boztepe H., Kapran Y., Tanakol R., Alagoel F., "Fas Ligand (FasL, Apo-1L/CD95L) Expression and Clinical Outcome in Papillary Microcarcinoma and Papillary Thyroid Carcinomas with Diameter Smaller than 1.5 Centimeters", EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, cilt.118, ss.537-543, 2010 | |
| dc.identifier.issn | 0947-7349 | |
| dc.identifier.other | av_886b89da-50d9-400c-8de4-17c81236684c | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/92573 | |
| dc.identifier.uri | https://doi.org/10.1055/s-0029-1241205 | |
| dc.description.abstract | Context: The presence and the importance of FasL (FasL, APO-1L/CD95L) in papillary microcarcinoma lesions which are smaller than 1.5 cm of the thyroid is unclear. | |
| dc.language.iso | eng | |
| dc.subject | İç Hastalıkları | |
| dc.subject | Endokrinoloji ve Metabolizma Hastalıkları | |
| dc.subject | Sağlık Bilimleri | |
| dc.subject | Dahili Tıp Bilimleri | |
| dc.subject | Tıp | |
| dc.subject | Klinik Tıp (MED) | |
| dc.subject | Klinik Tıp | |
| dc.subject | ENDOKRİNOLOJİ VE METABOLİZMA | |
| dc.title | Fas Ligand (FasL, Apo-1L/CD95L) Expression and Clinical Outcome in Papillary Microcarcinoma and Papillary Thyroid Carcinomas with Diameter Smaller than 1.5 Centimeters | |
| dc.type | Makale | |
| dc.relation.journal | EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES | |
| dc.contributor.department | İstanbul Üniversitesi , , | |
| dc.identifier.volume | 118 | |
| dc.identifier.issue | 8 | |
| dc.identifier.startpage | 537 | |
| dc.identifier.endpage | 543 | |
| dc.contributor.firstauthorID | 196915 | |
